Organon (Organon) Interest Expense : $-527 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Organon Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Organon's interest expense for the three months ended in Dec. 2023 was $ -129 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-527 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Organon's Operating Income for the three months ended in Dec. 2023 was $ 312 Mil. Organon's Interest Expense for the three months ended in Dec. 2023 was $ -129 Mil. Organon's Interest Coverage for the quarter that ended in Dec. 2023 was 2.42. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Organon Interest Expense Historical Data

The historical data trend for Organon's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Interest Expense Chart

Organon Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-258.00

-422.00

-527.00

Organon Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial													-119.00	-132.00	-132.00	-134.00	-129.00

Organon Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-527 Mil.

Organon (NYSE:OGN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Organon's Interest Expense for the three months ended in Dec. 2023 was $-129 Mil. Its Operating Income for the three months ended in Dec. 2023 was $312 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $8,751 Mil.

Organon's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	312	/	-129
	=	2.42

The higher the ratio, the stronger the company's financial strength is.

Warning Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Organon & Co interest coverage is 2.52, which is low.

Organon (Organon) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon & Co (NYSE:OGN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

OGN:Mexico 1OGN:Italy 0A9W:UK 7XP:Germany

Address

30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302

Website

https://www.organon.com

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada.

Executives

Kirke Weaver	officer: Gen. Counsel & Corp. Secy.	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Ma. Fatima Francisco	director	ONE PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202
Deborah H Telman	officer: General Counsel	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathryn Dimarco	officer: Corporate Controller	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Susanne Fiedler	officer: Chief Commercial Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Vittorio Nisita	officer: Head of Global Business Svcs	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Morrissey Joseph T. Jr.	officer: Head of Manufacturing	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aaron Falcione	officer: Chief Human Resources Officer	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Deborah R Leone	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martha E Mcgarry	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Phillip Ozuah	director	30 HUDSON STREET, FLOOR 33, JERSEY CITY NJ 07302
Geralyn S Ritter	officer: Hd of Ext. Affairs and ESG	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sandra Milligan	officer: Head of Research & Development	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Cynthia M Patton	director	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Alan Ezekowitz	director	C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139